

**DUR Committee Agenda**  
**October 11<sup>th</sup>, 2011**

**Office of MaineCare Services, Department of Health and Human Services**  
**442 Civic Center Drive, Augusta, Maine**  
**1:00 to 6:00 pm**

**Call to Order: 1:00 pm**

**Public Comments -Open Session 1:00-3:00 pm (estimated)**

**Old Business:**

**Approval of September Minutes (2 min)**

**Psych Work Group Monthly Update (2 min)**

**New Business: Annual PDL Review**

a) Closed session to discuss financials

b) Open session for New Drug Reviews (without Therapeutic Class Review)

1. **Complera**
2. **Cupvosa**
3. **Edurant**
4. **Firazyr**
5. **Sylatron**
6. **Teflaro**
7. **Yervoy**
8. **Zelboraf**
9. **Zytiga**

c) Open session to review and vote categories subject to potential changes.

(new drugs bolded and discussed in Therapeutic Class Reviews):

1. **Fluoroquinolones- Avelox** non-preferred
2. **Hepatitis C Agents- Incivek** and **Victrelis** preferred
3. **Oral Contraceptives- Seasonale** preferred, **LoSeasonique** non-preferred
4. **Diabetic Insulin- Levemir** non-preferred
5. **Diabetic-DPP-4 Agents- Tradjenta** non-preferred
6. **Incretin Mimetic- Byetta** step 8 and **Victoza** step 9
7. **Osteoporosis/Bone Agents- Xgeva, Prolia,** and **Zometa** non-preferred
8. **Angiotensin Modulators-** discussion
9. **Antiasthmatic- Beta- Adrenergics- Arcapta** non-preferred
10. **Antiasthmatic- Alpha- P. Inhibitor-** **Aralast** step 8, **Zemaira** step 8, **Glassia** step 9
11. **Phosphate Binders-** **Eliphos** preferred, **Phoslyra** non-preferred
12. **Antidepressants SSRI-** **Cymbalta**
13. **Antidepressants SNRI-** **Viibryd**
14. **Atypical Antipsychotics-** discussion
15. **Stimulants-** **Adderall XR,** **Intuniv**
16. **Analgesic Long Acting Narcotics- Nucynta ER** non-preferred, **Conzip** non-preferred
17. **Analgesic Short Acting Narcotics-** **Trezix** non-preferred
18. **NSAIDS-** **Sprix** non-preferred
19. **Anti-Migraine Agents-** **Maxalt** preferred
20. **Anticonvulsants-** **Horizant** non-preferred, **Gralise** non-preferred
21. **Anticoagulants-** **Xarelto** non-preferred, **Pradaxa**
22. **Platelet Aggregation Inhibitors-** **Brilinta** non-preferred

23. OPTH. Quinolones- Moxeza preferred
24. OPTH. Prostaglandins- Lumigan non-preferred
25. OPTH. Allergic Conjunctivitis- Optivar non-preferred

**Additional Drug Classes will require voting, please refer to draft PDL for all Therapeutic Drug Classes for discussion.**

**d) Closed session- discuss SSDC contracts, expected generics in 2012 and PDL strategy**

**Next meeting: November 8<sup>th</sup> 2011 6:00-8:00 pm**

**Adjournment: 6:00 pm**